Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Australian Journal of Primary Health|September 27, 2017
Case conferencing for palliative care patients - a survey of South Australian general practitionersTimothy H M To, Paul Tait, Deidre D Morgan, et al.
Surgery|August 29, 2007
Correlation between preoperative biliary drainage, bile duct contamination, and postoperative outcomes for pancreatic surgeryPaolo Limongelli, Madhava Pai, Dev Bansi, et al.
Annals of Surgical Oncology|June 9, 2016
Oncological Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysisMariano Cesare Giglio, Alexandros Giakoustidis, Ahmed Draz, et al.
Archives of Surgery (Chicago, Ill. : 1960)|October 22, 2008
Management of delayed postoperative hemorrhage after pancreaticoduodenectomy: a meta-analysisPaolo Limongelli, Shirin E Khorsandi, Madhava Pai, et al.
Australian Journal of General Practice|September 5, 2025
A National Core Community Palliative Care Medicines List for managing end-of-life symptomsLiz Reymond, Karen Cooper, Georgina Taylor, et al.
Future Oncology (London, England)|April 25, 2023
PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinomaPetros Fessas, Bernhard Scheiner, Antonio D'Alessio, et al.
Nuclear Medicine Communications|December 13, 2006
Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheresTeresa Szyszko, Adil Al-Nahhas, Paul Tait, et al.
BMC Cancer|February 22, 2018
Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinomaDavid J Pinato, Madhava Pai, Isabella Reccia, et al.
Oncotarget|June 1, 2016
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative studyDavid J Pinato, Tadaaki Arizumi, Jeong Won Jang, et al.
BMJ Open|November 20, 2025
Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiRMaria Qurashi, Maria Martinez, Caroline Ward, et al.
Pageof 4